Table 7.
Comparison of first-year growth for patients with IGHD who had all the characteristics of the best responders with those predicted to be poor responders
| Variable | Predicted best first-year HV SDS criterion n = 28 | Predicted poor first-year HV SDS criterion n = 29 |
|---|---|---|
| Baseline height SDS |
< −3 |
> −2.5 |
| Baseline BMI SDS |
> −0.5 |
< −1 |
| Pre-treatment HV (cm/yr) |
< 3.5 |
> 4 |
| Baseline height SDS minus mid-parental target height SDS |
> 3 |
< 2 |
| Maximum stimulated GH (ng/mL) |
≤ 4 |
≥ 7 |
| Female (n)/male (n) |
5/23 |
7/22 |
| |
Mean (SD) |
Mean (SD) |
| Baseline age (yr) |
6.5 (1.8) |
6.8 (2.0) |
| Baseline height SDS |
−4.1 (0.7) |
−1.9 (0.3) |
| Baseline BMI SDS |
0.5 (0.8) |
−1.5 (0.5) |
| Pre-treatment HV (cm/yr) |
1.9 (1.0) |
6.2 (1.9) |
| Baseline height SDS minus mid-parental target height SDS |
4.2 (0.7) |
1.4 (0.5) |
| Maximum stimulated GH (ng/mL) |
1.9 (1.0) |
8.6 (0.8) |
| First-year HV (cm/yr) |
13.1 (2.7) |
9.1 (2.3) |
| First-year Bakker HV SDS |
1.21 (1.3) |
−0.51 (0.9) |
| Second-year HV (cm/yr) |
8.5 (2.0) |
7.3 (1.4) |
| Second-year Bakker HV SDS | 0.33 (1.3) | −0.37 (0.8) |
BMI, body mass index; HV, height velocity; GH, growth hormone; SDS, standard deviation score.